UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Apple Turns 50: From Garage Startup to AI Crossroads 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
WALTHAM, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 8th Annual Biotech Showcase™ Conference on Monday, January 11, 2016 at 11:30 AM PST at the Parc 55 Hotel in San Francisco, CA.
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be available on Histogenics’ website for 30 days following the conference.
The Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Now in its eighth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals, as well as biopharmaceutical and life science company executives.
About Histogenics Corporation
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
